Jay Park*
With billions of dollars in investigate and improvement (R&D) financing proceeding to be contributed, the novel coronavirus infection 2019 (COVID-19) has ended up into a solitary center for the logical community. Be that as it may, the collective reaction from the logical communities have seen destitute return on venture, especially for helpful inquire about for COVID-19, uncovering the existing shortcomings and wasteful aspects of the clinical trial venture. In this article, we contend for the significance of basic changes to existing investigate programs for clinical trials in light of the lessons learned from COVID-19.
English 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi